This phenotype was observed less frequently when S-CAR T cells were transferred into wild-type mice, in which antigen stimulus was missing ( Supplementary Figure 3). These results showed that the majority of transferred S-CAR–grafted T cells remain functional even within the immunoregulatory hepatic microenvironment.

A profound reduction of the number of hepatocytes with cytoplasmic expression of HBV core protein (Figure 4A) showed the antiviral activity of the adoptively transferred S-CAR–grafted T cells. Moreover, the number of virions circulating in the bloodstream rapidly decreased 100-fold ( Figure 4B) and replicative forms of HBV DNA almost completely disappeared from the liver within 12 days ( Figure 4C and D). Lacking antiviral activity of CEA-CAR and SΔ-CAR engineered T cells proved that antigen recognition and T-cell activation via the S-CAR were PD0325901 supplier essential to stimulate the antiviral activity of adoptively transferred T cells. Animals injected with 4 × 106 S-CAR–grafted T cells did not lose weight over 34 days of treatment (Figure 5A) and did not show any obvious signs of distress, although serum TNF-α, IFN-γ, MCP-1, IL-10, and IL-6 levels increased significantly ( Figure 5B). Levels of immunoglobulin G1 antibodies increased, but levels

of other immunoglobulin subtypes were not altered ( Figure 5C). Twelve days selleck after transfer, the relative amount of CD4+ T cells and B cells decreased in the spleen and liver while B cells and NK cells increased in blood ( Figure 5D, left panel). The relative amount of myeloid immune cells such as inflammatory monocytes, DOK2 dendritic cells (DC), and neutrophils increased, especially in the liver ( Figure 5D, right panel). Thirty-four days after treatment, the composition of immune cells in all analyzed compartments resembled that of untreated mice again.

To compare the efficacy of S-CAR T cells with “natural” S-specific T cells, wild-type mice were immunized with recombinant HBsAg and boosted with modified vaccinia Ankara (MVA) virus expressing S-Protein to induce S-specific T cells for adoptive transfer (Supplementary Figure 4). A total of 1 × 106 S-specific CD8+ T cells and 1 × 106 and 4 × 106 S-CAR T cells were injected into HBVtg mice. Most of the vaccine-induced S-specific T cells accumulated in lymph nodes (Figure 6A), whereas S-CAR T cells preferentially homed to the liver ( Figures 2B and 6A). ALT levels were not elevated on day 7 in animals that received 1 × 106 S-specific T cells. Transfer of the same amount of S-CAR T cells led to an increase in ALT activity to approximately 150 U/L. Transfer of 4 × 106 S-CAR T cells led to an ALT activity of approximately 800 U/L ( Figure 6B). Accordingly, S-CAR T cells reduced cytoplasmic hepatitis B core antigen expression more profoundly than vaccine-induced T cells ( Figure 6C).